How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

AI researchers are no longer just saying that AGI is imminent — some are saying that it’s already arrived. In a cryptic but telling post on X, Aidan Clark — VP of Research (Training) at OpenAI — wrote ...

(1) (WorldWideWeb) The first Web browser, written by Tim Berners Lee and introduced in early 1991. It ran on the NeXT platform, which was also used as the first Web server. See NeXT. (2) (World Wide ...

Anthropic CEO Dario Amodei has been more precise, reportedly placing AGI arrival in 2026–2027 — a window that makes Musk’s “end of 2026” prediction less of an outlier than it might first appear.